FDA批准每周为早期阿尔茨海默氏症注射新的Leqembi针, 预定于10月6日启动。 FDA approves new weekly Leqembi injection for early Alzheimer's, set to launch October 6.

林业发展局批准了Leqembi的皮下自动注射器版本,这是治疗老年痴呆症的早期治疗,用于维持剂量。 The FDA has approved the subcutaneous autoinjector version of Leqembi, a treatment for early Alzheimer's disease, for maintenance dosing. 每周注射一次,从2025年10月6日开始,目的是减缓有轻度认知障碍或轻度痴呆的患者的疾病发展。 This weekly injection, available starting October 6, 2025, aims to slow disease progression in patients with mild cognitive impairment or mild dementia. 该治疗针对淀粉样斑块和原纤维，旨在更长时间地维持患者的认知能力。 The treatment targets amyloid plaque and protofibrils, aiming to maintain patients' cognitive abilities for longer. 新格式减少了对IV注剂及其相关保健资源的需求,有可能增加新病人的就医机会。 The new format reduces the need for IV infusions and their associated healthcare resources, potentially increasing access for new patients. 安全研究表明,其结果与四类治疗类似,但系统性反应较少。 Safety studies showed similar outcomes to IV treatments but with fewer systemic reactions.